US Dollar vs Yen

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

ホーム
投資
ETF
アメリカ
AMEX
Timothy Plan US Large Mid Cap Core ETF (TPLC)
Timothy Plan US Large Mid Cap Core ETF (TPLC) ニュース

Timothy Plan US Large Mid Cap Core ETF (TPLC)

49.02

-0.63

(-1.27%)

終了 6月7日 5:00AM

49.01

-0.01

(-0.02%)

取引時間後: 8:59AM

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

Certified Semi-annual Shareholder Report for Management Investment Companies (n-csrs)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM N-CSR...

Monthly Portfolio Investments Report on Form N-port (public) (nport-p)

Monthly Portfolio Investments Report on Form N-port (public) (nport-p)

Monthly Portfolio Investments Report on Form N-port (public) (nport-p)

Monthly Portfolio Investments Report on Form N-port (public) (nport-p)

Monthly Portfolio Investments Report on Form N-port (public) (nport-p)

Monthly Portfolio Investments Report on Form N-port (public) (nport-p)

Monthly Portfolio Investments Report on Form N-port (public) (nport-p)

Monthly Portfolio Investments Report on Form N-port (public) (nport-p)

Monthly Portfolio Investments Report on Form N-port (public) (nport-p)

Monthly Portfolio Investments Report on Form N-port (public) (nport-p)

Monthly Portfolio Investments Report on Form N-port (public) (nport-p)

Monthly Portfolio Investments Report on Form N-port (public) (nport-p)

DTGoody

DTGoody 4分前

We will be on entirely differently exchange then!

flipper44

flipper44 5分前

NWBO was entrusted with this technology well over decades ago. Their perseverance is commendable, but their execution, communication and red zone efficiency, and that of MHRA, are reasonably subject to scrutiny.

GR8 Dad

GR8 Dad 5分前

If you ride the o t c you're gonna lose some money, even a child knows that.

Make sure your winners are bigger than your losers.That's the only way to play it

Myth

Blow Wind Blow · Eric Clapton

https://www.youtube.com/watch?v=aE-QoPDxijc

DewDiligence

DewDiligence 6分前

Berobenatide—dosed monthly—appears_competitive_with_weekly Zepbound/Wegovy in efficacy/tolerability—see slide 7 at the link in #msg-177679183.

Berobenatide (f/k/a ‘3944) is the lead compound from PFE’s weight-loss pipeline acquired in the Metsera buyout (#msg-176942527).

joe botts

joe botts 6分前

tisdal

Nice Job on the Research CW. That opened my eyes to truly understand what the GARB Report's purpose was. That GARB Report was a preliminary document to establish hydrocarbon potential justifying the 3D Seismic, and after analyzing that data, if drilling would be justifiable.

The sta

FOFreddie

FOFreddie 8分前

The Brydon Fisher lawsuit was a Derivative lawsuit which would have returned the damages back to Fannie and Freddie for the benefit of shareholders. The Lamberth/Berkeley lawsuit is a Class Action but the issue so far is that damages were severely limited. We wait for the Decision on Restitution

DewDiligence

DewDiligence 12分前

ABT dual glucose/ketone CGMs facilitate_early_detection_of diabetic ketoacidosis (DKA):

https://www.prnewswire.com/news-releases/new-abbott-data-show-many-people-with-diabetes-may-not-recognize-symptoms-of-diabetic-ketoacidosis-302793024.html Findings from multiple Abbott studies sha

jour_trader

jour_trader 12分前

Would certainly be astronomical, just don’t think the odds are in our favor. We’ll know soon enough via lawsuit or cc if paragraph IV was pursued.

DewDiligence

DewDiligence 13分前

ABT dual glucose/ketone CGMs facilitate_early_detection_of diabetic ketoacidosis (DKA):

https://www.prnewswire.com/news-releases/new-abbott-data-show-many-people-with-diabetes-may-not-recognize-symptoms-of-diabetic-ketoacidosis-302793024.html Findings from multiple Abbott studies sha

JamesF1

JamesF1 13分前

I look at the possibility of Elite successfully getting a paragraph 4 approval for Eliquis as a long shot. Long shots occasionally come in.

DewDiligence

DewDiligence 13分前

FDA approval of ABT's dual glucose/ketone CGMs is coming soon; the products are already approved in Europe.

1plus1

1plus1 14分前

https://www.theguardian.com/football/2026/jun/06/mexico-security-world-cup-fan-zone-growing-protests-football >> LET'S HOPE THEY MENTION THE CO.

camelion

camelion 17分前

June flowers 💐!

Flobewan

Flobewan 17分前

Hey, somebody ate all my homemade banana cream ice cream, not only that but they ate all my chocolate/banana cream combo graham cracker crust pie. Now I gotta make more ice cream. Gonna see how chocolate/banana cream ice cream comes out.

And somehow my whole loaf of homemade bread dis

manibiotech

manibiotech 18分前

NICE has always said that they are Liaising with NWBO for years . Sommer is know what’s different that you are claiming ?

US Market News

US Market News 18分前

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using InsulinJune 6, 2026 2:45 PM
Business Wire Dexcom sponsored CONNECT randomized controlled trial expected to help establish new

joe botts

joe botts 19分前

Sorry 6' 1 here! Lol!!!!!!!

manibiotech

manibiotech 19分前

Agreed

If they wanted privacy and silence they should have stayed private and not took public money to pay their salaries and development and denied any accountability to the same public ( aka shareholders )

1plus1

1plus1 19分前

world cup starts in days >> biei /security should be involved >>https://www.fifa.com/en/tournaments/mens/worldcup/canadamexicousa2026/mexico/mexico-city

jimr1717

jimr1717 20分前

Has updated timeline 39Z-4 been updated?

researcher59

researcher59 22分前

SPCX - retail shares are not restricted, but Fidelity may limit access to futures IPOs for those who flip their shares in under 15 days.

The IPO may be oversubscribed, so if you ask for 50 shares you might only get 25.

https://www.businessinsider.com/spacex-ipo-fidelity

JimmyRich

JimmyRich 22分前

🙏🏼🙏🏼🙏🏼 my friend

Timothy Plan US Large Mi...

Franklin Templeton ICAV ...

Xilio Therapeutics

iShares Developed Market...

Essential Metals

Farm Pride Foods

Invesco S&P 500 High Bet...

BMO Equal Weight Industr...

Horizon Kinetics ISE Asi...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。